{
    "nctId": "NCT06481553",
    "briefTitle": "RWS of Paclitaxel Liposome Combined With Anti-HER-2 Monoclonal Antibody",
    "officialTitle": "Real-world Study of the Efficacy and Safety of Paclitaxel Liposome Combined With Anti-HER-2 Monoclonal Antibody as First-line Salvage Treatment of HER-2 Positive Advanced Breast Cancer",
    "overallStatus": "ACTIVE_NOT_RECRUITING",
    "conditions": "Breast Cancer Stage IV",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 480,
    "primaryOutcomeMeasure": "Overall Survival (OS)",
    "eligibilityCriteria": "inclusion criteria:\n\n1. Patients with unresectable or metastatic HER-2 positive breast cancer (immunohistochemistry 3+ or FISH positive) have received at least 2 cycles of salvage treatment with paclitaxel liposome in combination with anti-HER-2 therapy (monotherapy or dual-targeted therapy) \u00b1 other chemotherapy drugs (such as capecitabine, carboplatin, gemcitabine) as first-line treatment.\n2. Patients with no visceral metastases, but only have bone metastases or multiple lymph node metastases are eligible for inclusion.\n3. Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2. Expected survival of at least 3 months.\n\nexclusion criteria\uff1a\n\n1. Accompanied by other secondary malignant tumors.\n2. Male breast cancer or bilateral breast cancer.\n3. brain metastasis",
    "sex": "FEMALE",
    "minimumAge": "N/A",
    "stdAges": "CHILD, ADULT, OLDER_ADULT"
}